Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
Sponsor: Memorial Sloan Kettering Cancer Center
Summary
The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.
Official title: The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2020-07-09
Completion Date
2026-07
Last Updated
2025-08-08
Healthy Volunteers
No
Interventions
Clindamycin Phosphate
phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)
Triamcinolone Acetonide
triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change
Locations (8)
Northwestern University
Evanston, Illinois, United States
Tufts Medical Center
Boston, Massachusetts, United States
Washington University School of Medicine
St Louis, Missouri, United States
Hackensack Meridian Health
Hackensack, New Jersey, United States
Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (All Protocol Activities)
Hauppauge, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Columbia University
New York, New York, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States